<DOC>
	<DOCNO>NCT00732888</DOCNO>
	<brief_summary>This research study conduct University Pittsburgh Cancer Institute ( UPCI ) . It evaluate concentration Tasigna® , oral drug use treat type cancer , blood healthy volunteer take without Tums Ultra® , calcium product often use treatment upset stomach calcium supplement .</brief_summary>
	<brief_title>Effect Calcium Tasigna Pharmacokinetics ( PK ) Healthy Volunteers</brief_title>
	<detailed_description>This open-label , single-institution , randomize cross-over , fixed-schedule investigation effect calcium carbonate pharmacokinetics ( PK ) Tasigna® healthy volunteer . Healthy volunteer recruit participate study twelve subject ( 6 men / 6 woman ) complete study UPCI . Subjects compensated participation . Half subject receive Tasigna® alone Day 1 Tasigna® calcium carbonate Day 15 , half receive Tasigna® calcium carbonate Day 1 Tasigna® alone Day 15 , determine randomization subject receive either combination Tasigna® alone first visit . Doses 400 mg Tasigna® ( 2 x 200 mg tablet ) 4000 mg calcium carbonate ( 4 x Tums Ultra 1000® chewable tablet , equivalent 4000 mg calcium carbonate 1600 mg calcium ) . Multiple PK blood sample take Days 1-4 Days 15-18 . Tasigna® PK assess oral administration 400 mg Tasigna® alone , oral administration 400 mg Tasigna® concomitant administration 4000 mg calcium carbonate . Two two-day/one-night inpatient stay four brief outpatient visit require accommodate study procedure .</detailed_description>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Healthy men woman 18 year age old . Healthy subject define individual free clinically significant illness disease ( coronary arterial disease , chronic heart failure , bleed disorder , hypertension , chronic renal failure etc . ) determine medical history , physical examination , laboratory study . Body Mass Index ( BMI ) &lt; 31 kg/m2 ( weight/height2 ) . Female patient childbearing potential must negative pregnancy test within 14 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . Written , voluntary inform consent . Abnormal marrow function define leucocyte , neutrophil , platelet count outside normal limit . Any evidence renal dysfunction ( proteinuria ; serum creatinine &gt; upper limit normal ; serum creatinine &gt; upper limit normal , calculated creatinine clearance &lt; 60 mL/min/1.73 m2 ) . Impaired hepatic function ( liver enzymes great upper limit normal bilirubin outside normal range ) . QTcF &gt; 450 msec screen ECG ( use QTcF formula ) . Patient electrolyte abnormality ( e.g. , hypokalemia , hypomagnesemia , hypophosphatemia , hyperkalemia , hypocalcemia , hyponatremia ) . Taking medication ( include counter product ) , herbal product , mineral supplement vitamin ( daily multivitamin preparation ) , contraceptive ( woman ) , within 2 week start study . All form contraceptive medication permissible study would result female 's exclusion participation . Patients take medication chronic basis , antihypertensive medication thyroid replacement therapy , etc . eligible study . Subjects receive investigational agent within 28 day first day study drug dose . Female subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>No condition</keyword>
	<keyword>Pharmacokinetics study</keyword>
</DOC>